Aurion Biotech, a privately-owned company with offices in Seattle, Tokyo and Cambridge, Mass., is riding high after releasing positive topline data from its allogeneic cell therapy, AURN001, for corneal edema secondary to corneal endothelial dysfunction.
Aurion Biotech’s Ophthalmic Cell Therapy For The Masses
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
